PTCT
PTC Therapeutics Inc
Halal Rating :
Last Price
$43.92
Last updated:
Market Cap
-
7D Change
-0.31%
1 Year Change
61.04%
Company Overview
Industries
Exchange
Next Earnings Date
PTC Therapeutics is a biopharmaceutical company focused on discovering, developing, and commercializing clinically differentiated medicines that provide benefits to patients with rare disorders. The company's primary focus is on developing treatments for rare genetic disorders and diseases with significant unmet medical needs.
The company's portfolio includes approved products such as Translarna™ (ataluren), Emflaza® (deflazacort), and Upstaza™ (PTC-AADC), as well as a pipeline of clinical and pre-clinical candidates targeting rare diseases.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $196.79m | $251.3m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $186.7m | $226.92m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $210.12m | $255.57m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate PTC Therapeutics Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.